US Stock Market Movement: Brain Regeneration Technology Plunges on October 26 Due to Department of Justice Investigation Concerns, Overvaluation, and Expanding Losses

Brain Regeneration Technology October 26 Significant Decline Interpretation

Keywords: Department of Justice investigation concerns, overvaluation, expanding losses

1. On October 25, 2026, related reports mentioned concerns about a U.S. Department of Justice investigation and pointed out that the company's price-to-book ratio is significantly higher than the industry and peer levels; the reports also noted that the company has no product sales revenue and has received audit and internal control opinions.

2. On October 7, 2026, the company's annual report disclosed a net loss of approximately 11.7 million USD for the fiscal year ending June 30, 2026, higher than the approximately 3.58 million USD in the same period last year, and the company is still in the R&D stage with no generated revenue.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)